Palatin Technologies Inc New (PTN) Actualités

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update

Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update PR...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025

Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement

Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement PR...

Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide

Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide PR...

Palatin Provides Update on Anticipated 2025 Corporate Milestones

Palatin Provides Update on Anticipated 2025 Corporate Milestones PR Newswire CRANBURY, N.J., Jan. 28, 2025...

Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy

Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy PR...

Form 8-K - Current report

Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds

Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds PR Newswire CRANBURY...

Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis

Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]